HomeCompareAREVF vs PFE

AREVF vs PFE: Dividend Comparison 2026

AREVF yields 400000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AREVF wins by $5.011119029548644e+32M in total portfolio value
10 years
AREVF
AREVF
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full AREVF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AREVF vs PFE

📍 AREVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAREVFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AREVF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AREVF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AREVF
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AREVF beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AREVF + PFE for your $10,000?

AREVF: 50%PFE: 50%
100% PFE50/50100% AREVF
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AREVF
No analyst data
Altman Z
-128.2
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AREVF buys
0
PFE buys
0
No recent congressional trades found for AREVF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAREVFPFE
Forward yield400000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.011119029548644e+32M$49.6K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$5.010957816668433e+32M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AREVF vs PFE ($10,000, DRIP)

YearAREVF PortfolioAREVF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$40,010,700$40,000,000.00$9,153$693.39+$40.00MAREVF
2$149,615,521,729$149,572,710,280.37$8,593$849.25+$149615.51MAREVF
3$522,880,052,725,200$522,719,964,116,949.25$8,336$1,066.78+$522880052.72MAREVF
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$8,437$1,384.80+$1707862989289.04MAREVF
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$9,013$1,875.40+$5213509402845684.00MAREVF
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$10,306$2,680.72+$14874219058409543680.00MAREVF
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$12,820$4,101.38+$3.966119623405075e+22MAREVF
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$17,673$6,826.70+$9.88384363503273e+25MAREVF
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$27,543$12,591.86+$2.302052364743449e+29MAREVF
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$49,560$26,258.71+$5.011119029548644e+32MAREVF

AREVF vs PFE: Complete Analysis 2026

AREVFStock

AREV Life Sciences Global Corp., an integrated life science discovery company, produces and sells functional ingredients in Canada. The company's CBD-infused products, include Canna-Mulsion and NaturVax, anti- viral supplements; NaturRelax, a natural Sleep Aid; Natur Relief, an anti-inflator and pain relief product; and white label cannabis products, as well as a range of THC products, and cannabis skincare products and medicinal oils and edibles. Its ingredients are used in products that are targeted for sale in the natural health, medical, functional food, nutraceutical, sports nutrition, and bioceutical markets. In addition, the company's products address the areas of health, which include sleep deprivation, insomnia, anxiety, pain, and inflammatory conditions, as well as other specific ailments. Further, it offers nutraceutical product formulations under the Bare brand name; and ready-to-use therapeutic food products under the SUS-TAINN name. The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021. AREV Life Sciences Global Corp. was incorporated in 2005 and is based in Coquitlam, Canada.

Full AREVF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AREVF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AREVF vs SCHDAREVF vs JEPIAREVF vs OAREVF vs KOAREVF vs MAINAREVF vs JNJAREVF vs MRKAREVF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.